Please provide your email address to receive an email when new articles are posted on . Many men with lower life expectancy and localized prostate cancer get overtreated. Rates of definitive treatment ...

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The "striking" findings showed an ...

More than 1 in 5 older men with low life expectancy still undergo PSA screening for prostate cancer. More than 1 in 5 older men with low life expectancy still undergo PSA screening for prostate cancer ...

Clinicians must appropriately assess life expectancy and take steps to avoid prostate cancer overtreatment. Even in the active surveillance era, overtreatment persists among men with limited life ...

Watchful waiting was significantly associated with a low risk of prostate cancer progression and mortality among men with less than 10 years of life expectancy. Watchful waiting is an appropriate ...

National guidelines from associations such as the National Comprehensive Cancer Network (NCCN) and the American Urological Association recommend that men with a life expectancy of less than 10 years ...

Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than ...

Black men choose aggressive prostate cancer treatment—regardless of anticipated life expectancy—more often than Hispanic or Caucasian men, according to new research by Cedars-Sinai investigators ...